Single-cell RNA sequencing sheds light on stroke-induced brain damage

Strokes lead to irreversible damage to the brain and are one of the most common causes of dependency or death. As the cellular reactions to a cerebral infarction are not yet fully understood, there is a lack of possible approaches to promote the regeneration of damaged nerve tissue in the brain. A study led by MedUni Vienna and recently published in "Nature Communications" closes crucial gaps in our knowledge and paves the way for research into new, targeted therapeutic strategies.

In order to investigate the activity of individual cells in the brain after a stroke, the research team led by first author Daniel Bormann (Department of Thoracic Surgery) and study leaders Hendrik J. Ankersmit (Department of Thoracic Surgery) and Michael Mildner (Department of Dermatology) used single-cell RNA sequencing in animal models, which are already established in stroke research. Using this method, the researchers were able to identify different cell types and their reactions in the early phase after a cerebral infarction. They focussed on two specific cell types (astrocytes and oligodentrocytes) from the group of glial cells, which are involved in many fundamental processes in the brain.

Cellular interaction in the infarct area

Scientists already know that astrocytes divide rapidly after a stroke and accumulate around the infarct area.

We have been able to show, that oligodentrocyte precursor cells also divide in the acute infarct phase and accumulate at the edge of the damaged nerve tissue."

Daniel Bormann, First Author

In further complex analyses, the scientists discovered possible mechanisms in the wound healing of the damaged brain area: "We found considerable overlaps in the gene activity patterns of both cell types, especially in those genes that are important for building the glial barrier around the infarct," Bormann explains a remarkable detail from the study. In addition, it was discovered that certain immune cells (microglia and macrophages), which are also found in the vicinity of the infarct, release a signalling molecule (osteopontin). This molecule could play a decisive role in directing the glial cells to the edge of the infarct, where they are needed, among other functions, to form a barrier between the damaged and healthy tissue. "Our description of the interaction between immune and glial cells in the infarct area contributes considerably to a better understanding of the regeneration processes of nerve tissue in the brain after a stroke," says Daniel Bormann, summarising the significance of the results.

After cardiovascular diseases and cancer, strokes are the third most common cause of death in Austria and the most frequent cause of permanent disability and the need for long-term care. An ischaemic stroke is caused by the blockage of a blood vessel in the brain. The resulting interruption in the supply of oxygen and nutrients leads to a cerebral infarction in which nerve tissue is irreversibly damaged. Treatment approaches to date focus on restoring blood flow, which has to happen within 24 hours and is only possible for part of those affected. As the cellular processes following a cerebral infarction are not yet fully understood, treatment approaches to promote the regeneration of nerve tissue after a stroke are still lacking. "The insights gained in our international and interdisciplinary study are a promising resource for developing novel targeted therapeutic strategies," says Daniel Bormann with a view to further scientific investigations. 

Source:
Journal reference:

Bormann, D., et al. (2024). Single-nucleus RNA sequencing reveals glial cell type-specific responses to ischemic stroke in male rodents. Nature Communications. doi.org/10.1038/s41467-024-50465-z.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention